drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Individualized, gene-modified autologous CAR T-cell therapy targeting GPRC5D, using a fully human VHH binder with 4-1BB costimulatory and CD3ζ activation domains; administered as a single infusion (1.0–3.0×10^6 CAR-T cells/kg) after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a chimeric antigen receptor with a fully human VHH binder targeting GPRC5D and 4-1BB costimulatory plus CD3zeta activation domains. After lymphodepletion and infusion, CAR engagement of GPRC5D on malignant plasma cells triggers T-cell activation, expansion, and cytotoxic killing of GPRC5D-expressing cells.
drug_name
CAR-GPRC5D (RD118)
nct_id_drug_ref
NCT05759793